

Booster Dose Eligibility for Individuals Who Received Additional COVID-19 Vaccine Doses

Contents

Preamble.....	2
2-Dose Vaccines Non-Immunocompromised Including Clinically Vulnerable.....	3
Has Received THREE Doses Total.....	3
Has Received FOUR Doses Total.....	3
2-Dose Vaccines Moderately to Severely Immunocompromised	4
Has Received THREE Doses Total.....	4
Has Received FOUR Doses Total.....	4
1-Dose Vaccine Non-Immunocompromised Including Clinically Vulnerable	5
Has Received TWO Doses Total	5
Has Received THREE Doses Total.....	5
Non-Health Canada Authorized Vaccines Non-Immunocompromised Including Clinically Vulnerable.....	6
Has Received Non-Health Canada Authorized Vaccine (1 or 2 Doses).....	6
Appendix 1 – What is Considered a Booster Dose?.....	7
Appendix 2 – Definition of Moderately to Severely Immunocompromised	9
Appendix 3 – Definition of Clinically Vulnerable	9

Preamble

Up to two additional COVID-19 vaccine doses had been provided to some individuals in SK to complete a homologous mRNA series. An example when this may have happened is those travelling to jurisdictions in which their vaccine series was not recognized.

Now that booster doses are being provided, some of these additional doses may be considered Booster 1. This will depend on the number of doses, the intervals between doses, and the immune status of the individual. Note that as of May 6 2022, no additional doses are considered Booster 2 and anyone eligible for Booster 2 can receive it at least 4 months after their last dose regardless of the number of previous doses.

Steps to Determine if an Additional Dose is a Booster Dose:

1. Verify type, dose, and date of each vaccine given.
2. Determine the immune status of the individual.
3. Confirm the minimum intervals were met for the primary series doses (longer than recommended intervals are okay)
4. Calculate the interval between doses. For previously given doses, any additional dose given ≥ 3 months from a previous dose is considered a valid booster dose.
5. Determine if individual is eligible for additional booster doses.

The tables in this document are intended to help determine if additional doses are considered Booster 1 based on circumstances of individuals presenting to you. Empty rows are provided to record the doses of your specific scenarios.

Details of the specific intervals according to the categories presented in the tables are available in [Appendix 1](#).

A printable [algorithm](#) is also helpful in this process.

Note: when referring to intervals between COVID-19 vaccines doses, "months" refers to calendar months. For example, if an individual received a dose January 5, 2022, and is eligible for another dose at 3 months, the dose can be provided April 5, 2022 or later.

2-Dose Vaccines Non-Immunocompromised Including Clinically Vulnerable
 (AstraZeneca Vaxzevria™, Pfizer BioNTech Comirnaty™, and/or Moderna Spikevax™)

Non-Immunocompromised Individual Has Received THREE Doses Total

Examples:

Dose 1	Dose 2	Dose 3	Considered to Have Booster 1?
May 15	Jun 20	Sep 10 (< 3 months after Dose 2)	No Give Booster 1 ≥ 4 months after Dose 3 When eligible‡, give Booster 2 ≥ 4 months after Booster 1
May 15	Jun 20	Sep 30 (≥ 3 months after Dose 2)	Yes When eligible‡, give Booster 2 ≥ 4 months after last dose

* Eligibility criteria are outlined in the Summary Table tab on the [website](#).

Non-Immunocompromised Individual Has Received FOUR Doses Total

Examples:

Dose 1	Dose 2	Dose 3	Dose 4	Considered to Have Booster 1?
Jun 15	Jul 20	Aug 20 (< 3 months after Dose 2)	Oct 10 (< 3 months after Dose 2)	No Give Booster 1 ≥ 4 months after Dose 4 When eligible‡, give Booster 2 ≥ 4 months after Booster 1
Apr 15	May 20	Aug 20 (≥ 3 months after Dose 2)	Oct 30 (Irrelevant)	Yes When eligible‡, give Booster 2 ≥ 4 months after last dose
Jun 15	Jul 20	Aug 20 (< 3 months after Dose 2)	Oct 30 (≥ 3 months after Dose 2)	
Apr 15	Jun 20	Aug 20 (< 3 months after Dose 2)	Nov 30 (≥ 3 months after Dose 3)	
Apr 15	May 20	Aug 20 (≥ 3 months after Dose 2)	Nov 30 (Irrelevant)	

‡ Eligibility criteria are outlined in the Summary Table tab on the [website](#).

2-Dose Vaccines Moderately to Severely Immunocompromised

(AstraZeneca Vaxzevria™, Pfizer BioNTech Comirnaty™, Moderna Spikevax™)

Current guidance recommends that AstraZeneca Vaxzevria™ is not a preferred vaccine for moderately to severely immunocompromised individuals; however, some of these individuals may have received this vaccine. Any doses received are valid if the minimum interval has been met.

Moderately to Severely Immunocompromised Individual Has Received THREE Doses Total

- The primary series constitutes 3 doses; no doses are considered additional or boosters.
- Booster 1 is given ≥ 3 months from the last dose.
 - **Note** this interval is different from the interval to Booster 1 for non-immunocompromised (≥ 4 months) and is different from the interval to Booster 2 in non-immunocompromised and immunocompromised (both ≥ 4 months).

Moderately to Severely Immunocompromised Individual Has Received FOUR Doses Total

Examples:

Dose 1	Dose 2	Dose 3	Dose 4	Considered to Have Booster 1?
Jun 15	Jul 20	Aug 20	Oct 10 (< 3 months after Dose 3)	No Give Booster 1 ≥ 3 months after Dose 4 When eligible‡, give Booster 2 ≥ 4 months after Booster 1
Jun 15	Jul 20	Aug 20	Nov 30 (≥ 3 months after Dose 3)	Yes When eligible‡, give Booster 2 ≥ 4 months after last dose
Apr 15	May 20	Aug 20 [^]	Nov 30 (≥ 3 months after Dose 3)	

‡Eligibility criteria are outlined in the Summary Table tab on the [website](#).

[^] This example illustrates the third dose is considered completion of the primary series even if the interval is considerably > 28 days.

1-Dose Vaccine Non-Immunocompromised Including Clinically Vulnerable

(Janssen (Johnson & Johnson))

In SK, it is recommended to provide an additional mRNA dose \geq 2 months after the Janssen dose; this dose is considered Booster 1.

Non-Immunocompromised Individual Has Received TWO Doses Total

Examples:

Dose 1 (Janssen)	Dose 2 (mRNA)	Considered to Have Booster 1?
May 15	Jun 20 ($<$ 2 months after Dose 1)	No Give Booster 1 \geq 2 months after Dose 2 When eligible [†] , give Booster 2 \geq 4 months after Booster 1
May 15	Jul 20 (\geq 2 months after Dose 1)	Yes When eligible[†], give Booster 2 \geq 4 months after last dose

[†] Eligibility criteria are outlined in the Summary Table tab on the [website](#).

Non-Immunocompromised Individual Has Received THREE Doses Total

Examples:

Dose 1 (Janssen)	Dose 2 (mRNA)	Dose 3 (mRNA)	Considered to Have Booster 1?
May 15	Jun 20 ($<$ 2 months after Dose 1)	Jul 10 ($<$ 2 months after Dose 1)	No Give Booster 1 \geq 2 months after Dose 3 When eligible [†] , give Booster 2 \geq 4 months after Booster 1
May 15	Jun 20 ($<$ 2 months after Dose 1)	Aug 10 (\geq 2 months after Dose 1)	Yes When eligible[†], give Booster 2 \geq 4 months after last dose
May 15	Jun 20 ($<$ 2 months after Dose 1)	Sep 10 (\geq 2 months after Dose 2)	
May 15	Jul 20 (\geq 2 months after Dose 1)	Sep 20 (Irrelevant)	
May 15	Jul 20 (\geq 2 months after Dose 1)	Oct 30 (Irrelevant)	

[†] Eligibility criteria are outlined in the Summary Table tab on the [website](#).

Non-Health Canada Authorized Vaccines Non-Immunocompromised Including Clinically Vulnerable

Non-Immunocompromised Individual Has Received Non-Health Canada Authorized Vaccine (1 or 2 Doses)

Examples:

Dose 1	Dose 2	Dose 3	Dose 4	Considered to Have Booster 1?
Non-auth Mar 15	Non-auth Apr 20	mRNA Aug 20 (≥ 28 days after last non-auth)		No Dose 3 (=mRNA Dose 1) completes primary series Give Booster 1 ≥ 4 months after Dose 3
Non-auth Mar 15	Non-auth Apr 20	mRNA Jun 20 (≥ 28 days after last non-auth)	mRNA Aug 20 (< 3 months after mRNA Dose 1)	No Give Booster 1 ≥ 4 months after Dose 4
Non-auth Mar 15	Non-auth Apr 20	mRNA Jun 20 (≥ 28 days after last non-auth)	mRNA Sep 20 (≥ 3 months after mRNA Dose 1)	Yes When eligible‡, give Booster 2 ≥ 4 months after last dose
Non-auth Mar 15	Non-auth Apr 20	Non-auth May 30	mRNA Sep 20 (≥ 3 months after 3rd non-auth dose)	
Non-auth Mar 15	Non-auth Apr 20	Non-auth May 30	mRNA Aug 20 (< 3 months after 3rd non-auth dose)	No Give Booster 1 ≥ 4 months after Dose 4

‡ Eligibility criteria are outlined in the Summary Table tab on the [website](#).
Non-auth=COVID-19 vaccines that are not authorized by Health Canada

Appendix 1 – What is Considered a Booster Dose?

The criteria used to assess what additional doses constitute booster doses changed May 5, 2022. **Now, no previously received additional doses are considered Booster 2.** Assess to determine if any of the doses are considered Booster 1.

- If so, Booster 2 can be given, when eligible, at least 4 months after the last dose.
- If none of the previously received additional doses constitute Booster 1, the next dose can be received ≥ 4 months after the last dose and will be Booster 1.

2-Dose Vaccines - Non-Immunocompromised (Including Clinically Vulnerable)

(Pfizer BioNTech Comirnaty™, Moderna Spikevax™, AstraZeneca Vaxzevria™)

Those Who Have Received THREE Doses:

AZ, mRNA, mRNA

AZ, AZ, mRNA

mRNA, mRNA, mRNA

- If interval between Doses 2 and 3 is < 3 months, **considered to have no booster.** Next dose should be ≥ 4 months after last dose and will be Booster 1.
- If interval between Doses 2 and 3 is ≥ 3 months, **considered to have Booster 1.** If eligible, next dose should be ≥ 4 months after last dose and will be Booster 2.

Those Who Have Received FOUR Doses:

AZ, mRNA, mRNA, mRNA

AZ, AZ, mRNA, mRNA

- If interval between Doses 2 and 4 is < 3 months, **considered to have no booster.** Next dose should be ≥ 4 months after last dose and will be Booster 1.
- If interval between Doses 2 and 3 OR interval between Doses 3 and 4 OR interval between Doses 2 and 4 is ≥ 3 months, **considered to have Booster 1.** If eligible, next dose should be ≥ 4 months after last dose and will be Booster 2.

2-Dose Vaccines – Moderately to Severely Immunocompromised

(Pfizer BioNTech Comirnaty™, Moderna Spikevax™, AstraZeneca Vaxzevria™)

Current guidance recommends that AstraZeneca Vaxzevria™ is not a preferred vaccine for moderately to severely immunocompromised individuals; however, some of these individuals may have received this vaccine. Any doses received are valid if the minimum interval has been met.

Those Who Have Received THREE Doses:

AZ, mRNA, mRNA

AZ, AZ, mRNA

mRNA, mRNA, mRNA

- The primary series constitutes 3 doses, so these individuals are **considered to have no boosters.**
- Booster 1 is given ≥ 3 months[^] from the last dose.

^Note this interval is different from the interval to Booster 1 for non-immunocompromised (≥ 4 months) and is different from the interval to Booster 2 in non-immunocompromised and moderately to severely immunocompromised (both ≥ 4 months).

Those Who Have Received FOUR Doses:

AZ, mRNA, mRNA, mRNA

AZ, AZ, mRNA, mRNA

- If interval between Doses 3 and 4 is < 3 months, **considered to have no booster**. Next dose should be ≥ 3 months^ after last dose and will be Booster 1.
- If interval between Doses 3 and 4 is ≥ 3 months, **considered to have Booster 1**. If eligible, next dose should be ≥ 4 months after last dose and will be Booster 2.

^ Note this interval is different from the interval to Booster 1 for non-immunocompromised (≥ 4 months) and is different from the interval to Booster 2 in non-immunocompromised and moderately to severely immunocompromised (both ≥ 4 months).

1-Dose Vaccine – Non-Immunocompromised (Including Clinically Vulnerable)

(Janssen [Johnson & Johnson])

In SK, it is recommended to provide an additional mRNA dose ≥ 2 months after the Janssen dose; this dose is considered Booster 1.

Those Who Have Received TWO Doses

Janssen, mRNA

- If interval between Doses 1 and 2 is < 2 months, **considered to have no booster**. Next dose should be ≥ 2 months^ after last dose and will be Booster 1.
- If interval between Doses 1 and 2 is ≥ 2 months, **considered to have Booster 1**. If eligible, next dose should be ≥ 4 months after last dose and will be Booster 2.

^ Note this interval is different from the interval to Booster 1 for all others.

Those Who Have Received THREE Doses

Janssen, mRNA, mRNA

- If interval between Doses 1 and 3 is < 2 months, **considered to have no booster**. Next dose should be ≥ 2 months^ after last dose and will be Booster 1.
- If interval between Doses 1 and 2 OR interval between Doses 2 and 3 OR interval between Doses 1 and 3 is ≥ 2 months, **considered to have Booster 1**. If eligible, next dose should be ≥ 4 months after last dose and will be Booster 2.

^ Note this interval is different from the interval to Booster 1 for all others.

Non-Health Canada Authorized Vaccines – Non-Immunocompromised (Including Clinically Vulnerable)

- Individuals who have received 1 or 2 doses of a Non-Health Canada authorized vaccine should receive 1 mRNA dose to complete the primary series at least 28 days after the last dose.
 - Doses received after the 1st mRNA vaccine are assessed for eligibility as a booster dose.
- Individuals who have received 3 doses of a Non-Health Canada authorized vaccine do not need further vaccines to complete the primary series.

AZ = AstraZeneca Vaxzevria™

Appendix 2 – Definition of Moderately to Severely Immunocompromised

Moderately to severely immunocompromised individuals include those with the following conditions:

- Recipients of active treatment for solid tumour or hematologic malignancies
- Recipients of solid-organ transplant and taking immunosuppressive therapy
- Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate to severe primary immunodeficiency with associated humoral and/or cell-mediated immunodeficiency or immune dysregulation
- HIV with prior AIDS defining illness OR prior CD4 count $\leq 200/\text{mm}^3$ OR prior CD4 fraction $\leq 15\%$ OR perinatally acquired HIV infection
- Recipients of active treatment with the following categories of immunosuppressive therapies:
 - anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22)
 - high-dose systemic corticosteroids (prednisone equivalent of ≥ 40 mg per day for more than 1 week)
 - alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive

Appendix 3 – Definition of Clinically Vulnerable

While these individuals are considered clinically vulnerable, they are not considered moderately to severely immunocompromised and, therefore, are categorized as non-immunocompromised

Individuals considered clinically vulnerable include those:

- with severe respiratory conditions, including all cystic fibrosis, severe asthma, and severe chronic obstructive pulmonary disease (COPD)
- with rare diseases that significantly increase the risk of infections (such as homozygous sickle cell disease)
- who had their spleen removed
- with very significant developmental disabilities that increase risk (such as Down's syndrome)
- on dialysis or with chronic kidney disease (stage 5)
- with significant neuromuscular conditions requiring respiratory support
- with diabetes (any type)